摘要
目的评估非小细胞肺癌(NSCLC)行阿帕替尼联合放疗治疗的临床疗效。方法60例非小细胞肺癌患者,随机分为对照组及观察组,各30例。对照组给予常规放疗,观察组给予阿帕替尼联合放疗。比较两组患者治疗前后的肿瘤标志物水平,临床疗效,不良反应发生情况,治疗后6个月、1年生存情况。结果治疗后,两组患者的癌胚抗原(CEA)、细胞角蛋白19血清片段211(CYFRA211)水平均较本组治疗前降低,且观察组降低程度优于对照组,差异均具有统计学意义(P<0.05)。观察组患者的总有效率为83.3%,高于对照组的56.7%,差异有统计学意义(P<0.05)。两组患者的蛋白尿、转氨酶升高、骨髓抑制、凝血异常发生率对比,差异均无统计学意义(P>0.05);观察组患者的手足综合征、高血压发生率分别为26.7%、26.7%,均高于对照组的6.7%、3.3%,差异均具有统计学意义(P<0.05)。观察组患者治疗后6个月、1年的生存率分别为80.0%、60.0%,均高于对照组的53.3%、33.3%,差异均具有统计学意义(P<0.05)。结论阿帕替尼联合放疗治疗非小细胞肺癌,对患者肿瘤标志物水平改善作用显著,疗效可靠,且不增加不良反应,患者可耐受,值得临床借鉴。
Objective To evaluate the clinical efficacy of apatinib combined with radiotherapy in the treatment of non-small cell lung cancer(NSCLC).Methods A total of 60 patients with non-small cell lung cancer were randomly divided into control group and observation group,with 30 cases in each group.The control group received radiotherapy,and the observation group received apatinib combined with radiotherapy.The level of tumor markers before and after treatment,clinical efficacy,occurrence of adverse reactions,and survival at 6 months and 1 year after treatment were compared between the two groups.Results After treatment,the levels of carcinoembryonic antigen(CEA),cytokeratin 19 serum fragment 211(CYFRA211)in the two groups were lower than those before treatment,and the decrease degree of the observation group was better than that of the control group.Their difference was statistically significant(P<0.05).The total effective rate of the observation group was 83.3%,which was higher than 56.7%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of proteinuria,transaminase elevation,myelosuppression and coagulation abnormality between the two groups(P>0.05).The hand-foot syndrome and high blood pressure were 26.7%and 26.7%respectively in the observation group,which were all higher than 6.7%and 3.3%in the control group,and their difference was statistically significant(P<0.05).The survival rate at 6 months and 1 year after treatment were 80.0%and 60.0%respectively in the observation group,which was higher than 53.3%and 33.3%in the control group,and their difference was statistically significant(P<0.05).Conclusion Combination of apatinib and radiotherapy shows reliable efficacy for patients with non-small cell lung cancer,and it can significantly improve the level of tumor markers without increasing adverse reactions.Patients are tolerable,and it is worth clinical reference.
作者
李花妮
陈玉茹
王晴
和劲光
LI Hua-ni;CHEN Yu-ru;WANG Qing(Heze Municipal Hospital,Heze 274000,China)
出处
《中国实用医药》
2020年第8期14-16,共3页
China Practical Medicine
关键词
阿帕替尼
放疗
非小细胞肺癌
肿瘤标志物
不良反应
Apatinib
Radiotherapy
Non-small cell lung cancer
Tumor markers
Adverse reactions
